| INTRODUCTION
Adenoid cystic carcinoma (ACC) is the second most common malignant tumor in the salivary glands, accounting for 10% of all salivary neoplasms. 1 It remains a poorly understood disease because of its unpredictable nature, perineural invasion, and high rate of distant dissemination. 1, 2 Although advancements have been made in the treatment options for ACC patients, especially in molecular targeting therapy, the long-term survival is considered poor, with 10-year survival rate of 37%-65%. 2, 3 Therefore, it is critical to identify novel therapeutic targets and develop potential therapeutic strategies for ACC.
NOXA which encodes a Bcl-2 homology 3 (BH3), but not other BH domains 4 is subset of the Bcl-2 family of proteins. The NOXA promoter region comprises several enhancer elements located upstream of the actual gene locus. 4 Moreover, the NOXA promoter region contains binding sites for more than 40 different transcription factors suggesting that NOXA can be differentially activated by multiple intracellular or extracellular signals. 4, 5 In several studies, Liang and Weng contributed equally to this work.
transcriptional activation of NOXA can effectively trigger apoptosis and susceptibility of cancer cells to therapy-induced apoptosis. [6] [7] [8] Independent of its pro-apoptotic function, Elgendyet al 9 showed that high expression of Noxa, induced by oncogenic Ras, can lead to excessive autophagy and result in cell death. These data clearly suggest multiple roles of Noxa in cancer, but the specific role of Noxa in ACC is not clear.
In our study, we investigated NOXA expression in ACC cell lines and clinical tissues and found critical roles for Noxa in modulating the cell proliferation, apoptosis, and autophagy, which provided crucial evidences in the understanding of the role of Noxa in ACC. 
| MATERIAL AND METHODS

| Tissues and cells
| RNA extraction and quantitative real-time
PCR
Total RNA extraction and detection of relative mRNAs (NOXA, P27, FASL, BAX, P21, CAPS3, BECN1, ATG5, LC3, ATG12, and P53) were performed as previously described. 10 The housekeeping gene β-actin was used as an internal control. The sequences of the primers are listed in Table 1 . We used 2 −ΔΔ CT method to quantify the relative gene expression.
| Plasmid constructs and siRNAs
For overexpression constructs, human NOXA and P53 cDNAs were The sense strand sequences of siRNAs were as follows:
NOXA-siRNA, 5′-GGCCGUCUUUGAAGACUUA-3′, P53-siRNA, 5′ -GGGCCUGCUAUAACUUGUU-3′.
| Flow cytometry analysis
Cells were collected and incubated in the Annexin V Binding Buffer.
The Dead Cell Apoptosis Kit with Alexa® Fluor 488 annexin V and PI assay kit (Life Technologies, Carlsbad, CA, USA) was used to quantify the apoptosis level.
| Colony formation and MTT assay
For colony formation assay, 500 cells were seeded in 6-well cluster plates (Corning, NY, USA) and cultured in complete medium for 14 days. A group of 50 cells or more was counted as a colony, and the experiment was performed in triplicate. MTT assay was performed as previously described. 
| Western blot analysis
Western blotting was performed as previously described. 10 The primary antibodies were used: anti-caspase 3, anti-FASL, and anti-LC3 (1:500, Cell Signaling Technology, Danvers, MA, USA); anti-T A B L E 1 Sequences of the primers used in quantitative real-time PCR
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Beclin1, anti-Bim, anti-Atg5, and anti-GAPDH (1:1000, Cell Signaling Technology).
| Animal study
The research was approved by the Ethical Committee on Animal Research of the Sun Yat-sen University. The animal experimental procedures were performed according to our previous protocol. 10 SACC-83 cell line which is overexpression of Noxa or control SACC-83 cell line which is transfected with vectors were injected sub-cutaneously into the dorsal region of BALB/c nude mice to establish tumors. There were four mice in each group.
| Immunohistochemistry
Immunohistochemical analysis on the xenograft and ACC tissue were performed according to our previous protocol 11 to investigate the Noxa expression. The primary antibodies were used: anti-Noxa
(1:1000, Cell Signaling Technology). Luciferase and Renilla signals were measured 36 hours after transfection using a Dual Luciferase Reporter Assay Kit (Promega).
| Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using a Magna ChIP kit (Millipore, Billerica, MA, USA) as previously described. 12 Precipitates using anti-p53
(Cell Signaling Technology) and irrelevant IgG were heated at 65°C for 4 hours to reverse the formaldehyde cross-linking. Real-time quantitative was performed using primers 5′-CGTGTCCGGGCAGGTCGCGC T-3′ and 5′-TGACGTAGGGAAACTAGACG-3′ that generate a DNA fragment containing the NOXA and P53 sites.
| Statistics
All statistical analyses were performed using SPSS 18.0 statistical software (SPSS Inc., Chicago, IL, USA). Statistical differences were determined by the two-tailed Student's t test between two groups of data; a P value <0.05 was considered statistically significant. Figure 1C ).
| Noxa inhibits proliferation in ACC cells
To verify the effect of Noxa on ACC cell proliferation, ACC cell line Figure 3C,D) . These results suggested that in addition to apoptosis, the autophagy was also activated by Noxa in ACC cells.
| Noxa induces apoptosis in ACC cells
| Noxa induces autophagy in ACC cells
| Expression of Noxa inhibits the tumor growth of ACC in vivo
The in vivo results demonstrated that overexpression of Noxa in SACC-83 cell line inhibits tumor growth comparing with the negative control ( Figure 4A-C) . On day 40, tumors were removed and immunohistochemistry was performed to determine the expression levels of Noxa in xenograft. As shown in Figure 4D , Noxa staining intensity is strong in the tumor growth inhibition group but weak in the negative vector group. These data provided strong evidence that overexpression of Noxa inhibits in vivo tumor growth of ACC cells.
| Noxa is transcriptionally up-regulated by p53
It is widely known that NOXA is a p53-target gene in several tumors. We wanted to explore whether Noxa expression in ACC was also associated with the p53 pathway. As shown in Figure 5A , Figure 5E , PCR product in the anti-p53 chromatin immunoprecipitation (ChIP) with the putative p53-binding site sequence primer was significantly higher than in the negative control revealing that p53 directly binds to the sequence. NOXA and P53 mRNA expression in 10 ACC tissues showed that NOXA levels are positively correlated with P53 expression level ( Figure 5F ). In summary, these results suggest that p53 can directly bind to the promoter of NOXA and promote its transcription.
| DISCUSSION
In this study, we showed that Noxa suppressed the proliferation of ACC cells. Moreover, we found that Noxa played an important regulatory role at the cross talk of autophagy and apoptosis. Finally, we
show that the transcriptional activity of NOXA gene could be enhanced by p53 in ACC.
Previous evidence has demonstrated that various inducers and pathways of cell stress, including DNA damage, 13 endoplasmic reticulum stress, 14 hypoxia, 15 and growth-factor deprivation 16 enhance expression of Noxa, and link to cell death in various hematopoietic and solid cancers. Moreover, it is reported that induction of Noxa enhanced susceptible of cancer cells to chemotherapeutic drugs, 17 which could be a feasible and effective method to improve efficiency of cancer treatment. In this study, we illustrated that NOXA is down-regulated in human ACC, and patients with lower expression level of NOXA had a significantly poorer overall survival, and enhancing its expression inhibits the growth of ACC cells.
Apoptosis has long been regarded as a major regulatory role in cell survival. However, autophagy is fast achieving an important position. The precise role of autophagy in cancer is still controversy. In certain circumstances, autophagy can promote cancer cell survival and suppress apoptosis. 18 As we have shown previously, inhibition of autophagy increases cisplatin cytotoxicity and promotes apoptosis in ACC cells of salivary glands. 19 However, in other cancers, induction of autophagy promotes apoptotic by chemotherapeutic drugs. 20 As a result, the cross talk between autophagy and apoptosis may play important roles in cancer treatment. Beclin 1, Atg5, and Bim were found as regulators and effectors of both autophagy and apoptosis, and here we found them to be downstream targets of Noxa. 4 Our data suggest that Noxa regulated the apoptotic proteins such as caspase 3, p21, FASL, and Bim and autophagy-related genes such as Beclin 1, Atg5, and LC3. It suggested that Noxa induced both apoptosis and autophagy in ACC cells. It is our next challenge to identify how the pathways involving these genes are integrated to result in the final growth regulation outcome.
Studies have found that p53 can induce both apoptosis and autophagy in tumors, while the mechanism how p53 orchestrates apoptosis and autophagy is still unclear. P53-induced apoptosis and autophagy are regulated, at least in part, by transcriptional activation of its target genes. Preliminary evidence indicated that NOXA is a primary p53-response gene. NOXA mRNA and protein are significantly up-regulated after overexpression of p53; furthermore, Noxa play an important role in p53-induced apoptosis. 21 However, several recent studies have found that the Noxa expression in some tumors is not mediated via p53, and occurs in p53 deficient patient samples. 12 In this study, we illustrated that the expression level of NOXA is positively correlated with P53 level.
ChIP and Luciferase study indicating that p53 can bind to the NOXA promoter and promote its transcription. These results suggest that Noxa may play a pivotal role in p53-induced apoptosis and autophagy.
| CONCLUSIONS
In conclusion, Noxa is transcriptionally activated by the p53 and plays important roles in cell growth, apoptosis, and autophagy in ACC.
